Optimizing Treatments for Heart Failure During Hospitalization

Not yet recruiting

• Conditions: Decompensated Heart Failure

• Registration Number: NCT05910437
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

Heart failure reaches 1.5 million people in France and is responsible for 200,000 hospitalizations per year.

Over the past ten years, new therapies have emerged (treatment of martial deficiency, Entresto, iSGLT2).

Hospitalization in a context of acute heart failure is a moment of choice in the history of the disease to introduce recommended treatments under closer supervision (clinical, biological) than in ambulatory, and allows a decrease in hospitalizations, morbidity and mortality.

The purpose of this study is to describe the introduction of heart failure drugs (including iSGLT2) in real-life settings in patients hospitalized for decompensated heart failure.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-04-28
• Study First Submitted QC: 2023-06-15
• Study First Posted: 2023-06-18
• Status Verified: 2023-08
• Last Update Submitted: 2023-08-11
• Last Update Posted: 2023-08-14
• Study Start: 2023-09
• Primary Completion: 2024-07
• Study Completion: 2024-07

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Patient ≥ 18 years
• Hospitalized (≥24h) for decompensated heart failure in cardiology.

Exclusion Criteria

• Patient opposition participation in research and use of data.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Prescription score	During hospitalisation for decompensated heart failure (up to 10 days)	Prescription score, ranging from 0 to 10, each type of heart failure treatment (IEC/ARA2, Sacubitril, betablockers, SGLT2i, MRA) being evaluated on a scale of 2.

Secondary Outcome Measures

Name	Time	Method
serum concentration of creatinine	During hospitalisation for decompensated heart failure (up to10 days)	Creatinine measured at admission and discharge
serum concentration of potassium	During hospitalisation for decompensated heart failure (up to 10 days)	Potassium measured at admission and discharge
Concentration of hemoglobin	During hospitalisation for decompensated heart failure (up to 10 days)	hemoglobin measured at admission and discharge
All cause Death	6 months
Rate of hospitalization for heart failure	6 months

Trial Locations

Locations (2)

CHRU de NANCY; 🇫🇷 Vandœuvre-lès-Nancy, France

Chr Metz Thionville; 🇫🇷 Ars-Laquenexy, France